Lung mass laboratory findings: Difference between revisions
Jump to navigation
Jump to search
| Line 42: | Line 42: | ||
| pmid = 6757872 | | pmid = 6757872 | ||
}}</ref><ref name="Bowman2018">{{cite journal|last1=Bowman|first1=Brendan T.|title=Electrolyte Disorders Associated with Cancer|journal=Journal of Onco-Nephrology|volume=1|issue=1|year=2018|pages=30–35|issn=2399-3693|doi=10.5301/jo-n.5000004}}</ref> | }}</ref><ref name="Bowman2018">{{cite journal|last1=Bowman|first1=Brendan T.|title=Electrolyte Disorders Associated with Cancer|journal=Journal of Onco-Nephrology|volume=1|issue=1|year=2018|pages=30–35|issn=2399-3693|doi=10.5301/jo-n.5000004}}</ref> | ||
:*Raised serum [[alkaline phosphatase]]<ref>{{Cite journal | :*Raised [[serum]] [[alkaline phosphatase]]<ref>{{Cite journal | ||
| author = [[Fusun Alatas]], [[Ozkan Alatas]], [[Muzaffer Metintas]], [[Omer Colak]], [[Sinan Erginel]] & [[Emel Harmanci]] | | author = [[Fusun Alatas]], [[Ozkan Alatas]], [[Muzaffer Metintas]], [[Omer Colak]], [[Sinan Erginel]] & [[Emel Harmanci]] | ||
| title = Usefulness of bone markers for detection of bone metastases in lung cancer patients | | title = Usefulness of bone markers for detection of bone metastases in lung cancer patients | ||
| Line 53: | Line 53: | ||
| pmid = 12135691 | | pmid = 12135691 | ||
}}</ref> | }}</ref> | ||
:*Deranged levels of [[alanine aminotransferase | :*Deranged levels of [[alanine aminotransferase|alanine aminotransferase (ALT)]] and [[aspartate aminotransferase|aspartate aminotransferase (AST)]] | ||
:*Serum [[bilirubin]] has a negative association with the decline in FEV1 and FVC and a positive association with the decline in FEV1/FVC<ref>{{Cite journal | :*[[Serum]] [[bilirubin]] has a negative association with the decline in [[FEV1]] and [[FVC]] and a positive association with the decline in [[FEV1/FVC ratio|FEV1/FVC]]<ref>{{Cite journal | ||
| author = [[Ah Young Leem]], [[Ha Yan Kim]], [[Young Sam Kim]], [[Moo Suk Park]], [[Joon Chang]] & [[Ji Ye Jung]] | | author = [[Ah Young Leem]], [[Ha Yan Kim]], [[Young Sam Kim]], [[Moo Suk Park]], [[Joon Chang]] & [[Ji Ye Jung]] | ||
| title = Association of serum bilirubin level with lung function decline: a Korean community-based cohort study | | title = Association of serum bilirubin level with lung function decline: a Korean community-based cohort study | ||
| Line 77: | Line 77: | ||
| pmid = 24177000 | | pmid = 24177000 | ||
}}</ref> | }}</ref> | ||
:*Elevated serum lactate dehydrogenase (LDH)<ref>{{Cite journal | :*Elevated [[serum]] [[Lactate dehydrogenase|lactate dehydrogenase (LDH)]]<ref>{{Cite journal | ||
| author = [[P. Ray]], [[X. Quantin]], [[J. Grenier]] & [[J. L. Pujol]] | | author = [[P. Ray]], [[X. Quantin]], [[J. Grenier]] & [[J. L. Pujol]] | ||
| title = Predictive factors of tumor response and prognostic factors of survival during lung cancer chemotherapy | | title = Predictive factors of tumor response and prognostic factors of survival during lung cancer chemotherapy | ||
| Line 88: | Line 88: | ||
| pmid = 9674872 | | pmid = 9674872 | ||
}}</ref> | }}</ref> | ||
:*Elevated serum tissue polypeptide-specific antigen (TPS)<ref>{{Cite journal | :*Elevated [[serum]] tissue polypeptide-specific antigen (TPS)<ref>{{Cite journal | ||
| author = [[P. Ray]], [[X. Quantin]], [[J. Grenier]] & [[J. L. Pujol]] | | author = [[P. Ray]], [[X. Quantin]], [[J. Grenier]] & [[J. L. Pujol]] | ||
| title = Predictive factors of tumor response and prognostic factors of survival during lung cancer chemotherapy | | title = Predictive factors of tumor response and prognostic factors of survival during lung cancer chemotherapy | ||
Latest revision as of 19:43, 24 June 2019
|
Lung Mass Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Lung mass laboratory findings On the Web |
|
American Roentgen Ray Society Images of Lung mass laboratory findings |
|
Risk calculators and risk factors for Lung mass laboratory findings |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Maria Fernanda Villarreal, M.D. [2] Akshun Kalia M.B.B.S.[3]
Overview
Laboratory findings associated with lung mass varies with the underlying presentation. The findings may range from normal to severely elevated. In general, a thorough laboratory evaluation is necessary to accurately assess, diagnose and stage the severity of lung mass. Laboratory evaluations include complete blood count, electrolytes, serum calcium, alkaline phosphatase (ALP), alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin, serum creatinine, albumin, and lactate dehydrogenase.
Laboratory Findings
Laboratory findings associated with lung mass include:[1]
- Anemia on complete blood count[2][3]
- Electrolytes imbalance[4][5]
- Raised serum alkaline phosphatase[6]
- Deranged levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST)
- Serum bilirubin has a negative association with the decline in FEV1 and FVC and a positive association with the decline in FEV1/FVC[7][8]
- Elevated serum lactate dehydrogenase (LDH)[9]
- Elevated serum tissue polypeptide-specific antigen (TPS)[10]
References
- ↑ Spira A, Ettinger DS (2004). "Multidisciplinary management of lung cancer". N. Engl. J. Med. 350 (4): 379–92. doi:10.1056/NEJMra035536. PMID 14736930.
- ↑ Katarzyna A. Zablocka-Slowinska, Monika Kosacka, Irena Porebska, Konrad Pawelczyk, Marcin Golecki, Jadwiga Biernat & Halina Grajeta (2017). "The usefulness of routinely used malnutrition screening tools in predicting anemia in lung cancer patients". Advances in clinical and experimental medicine : official organ Wroclaw Medical University. 26 (9): 1383–1389. doi:10.17219/acem/65785. PMID 29442459. Unknown parameter
|month=ignored (help) - ↑ Qianjun Zhou, Guangzhong Lu, Aiqun Liu & Tadasu Kohno (2012). "Extraskeletal myxoid chondrosarcoma in the lung: asymptomatic lung mass with severe anemia". Diagnostic pathology. 7: 112. doi:10.1186/1746-1596-7-112. PMID 22925697. Unknown parameter
|month=ignored (help) - ↑ S. G. Cunningham (1982). "Fluid and electrolyte disturbances associated with cancer and its treatment". The Nursing clinics of North America. 17 (4): 579–593. PMID 6757872. Unknown parameter
|month=ignored (help) - ↑ Bowman, Brendan T. (2018). "Electrolyte Disorders Associated with Cancer". Journal of Onco-Nephrology. 1 (1): 30–35. doi:10.5301/jo-n.5000004. ISSN 2399-3693.
- ↑ Fusun Alatas, Ozkan Alatas, Muzaffer Metintas, Omer Colak, Sinan Erginel & Emel Harmanci (2002). "Usefulness of bone markers for detection of bone metastases in lung cancer patients". Clinical biochemistry. 35 (4): 293–296. PMID 12135691. Unknown parameter
|month=ignored (help) - ↑ Ah Young Leem, Ha Yan Kim, Young Sam Kim, Moo Suk Park, Joon Chang & Ji Ye Jung (2018). "Association of serum bilirubin level with lung function decline: a Korean community-based cohort study". Respiratory research. 19 (1): 99. doi:10.1186/s12931-018-0814-z. PMID 29792214. Unknown parameter
|month=ignored (help) - ↑ Ivan Curjuric, Medea Imboden, Martin Adam, Robert W. Bettschart, Margaret W. Gerbase, Nino Kunzli, Thierry Rochat, Lucia Rohrer, Thomas B. Rothe, Joel Schwartz, Daiana Stolz, Jean-Marie Tschopp, Arnold von Eckardstein, Florian Kronenberg & Nicole M. Probst-Hensch (2014). "Serum bilirubin is associated with lung function in a Swiss general population sample". The European respiratory journal. 43 (5): 1278–1288. doi:10.1183/09031936.00055813. PMID 24177000. Unknown parameter
|month=ignored (help) - ↑ P. Ray, X. Quantin, J. Grenier & J. L. Pujol (1998). "Predictive factors of tumor response and prognostic factors of survival during lung cancer chemotherapy". Cancer detection and prevention. 22 (4): 293–304. PMID 9674872.
- ↑ P. Ray, X. Quantin, J. Grenier & J. L. Pujol (1998). "Predictive factors of tumor response and prognostic factors of survival during lung cancer chemotherapy". Cancer detection and prevention. 22 (4): 293–304. PMID 9674872.